Literature DB >> 25304536

Traditional and innovative experimental and clinical trial designs and their advantages and pitfalls.

Katja Weimer1, Paul Enck.   

Abstract

Many study designs and design variants have been developed in the past to either overcome or enhance drug-placebo differences in clinical trials or to identify and characterize placebo responders in experimental studies. They share many commonalities as well as differences that are discussed here: the role of deception and ethical restrictions, habituation effects and the control of the natural course of disease, assay sensitivity testing and effective blinding, acceptability and motivation of patients and volunteers, and the development of individualized medicine. These are fostered by two opposite strategies: utilizing the beneficial aspects of the placebo response-and avoiding its negative counterpart, the nocebo effect-in medical routine for the benefit of patients, and minimizing-by controlling-the negative aspects of the placebo effect during drug development.

Entities:  

Mesh:

Year:  2014        PMID: 25304536     DOI: 10.1007/978-3-662-44519-8_14

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  10 in total

Review 1.  Placebo eff ects in psychiatry: mediators and moderators.

Authors:  Katja Weimer; Luana Colloca; Paul Enck
Journal:  Lancet Psychiatry       Date:  2015-03       Impact factor: 27.083

Review 2.  Age and sex as moderators of the placebo response – an evaluation of systematic reviews and meta-analyses across medicine.

Authors:  Katja Weimer; Luana Colloca; Paul Enck
Journal:  Gerontology       Date:  2015       Impact factor: 5.140

3.  Side effects can enhance treatment response through expectancy effects: an experimental analgesic randomized controlled trial.

Authors:  Chantal Berna; Irving Kirsch; Sean R Zion; Yvonne C Lee; Karin B Jensen; Pamela Sadler; Ted J Kaptchuk; Robert R Edwards
Journal:  Pain       Date:  2017-06       Impact factor: 6.961

4.  Failure of Placebo Analgesia Model in Rats with Inflammatory Pain.

Authors:  Xiang-Sha Yin; Jin-Yu Yang; Shuai Cao; Yun Wang
Journal:  Neurosci Bull       Date:  2019-08-21       Impact factor: 5.203

5.  Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population.

Authors:  Alberto Revelli; Grazia Pettinau; Gemma Basso; Andrea Carosso; Alessandro Ferrero; Cecilia Dallan; Stefano Canosa; Gianluca Gennarelli; Daniela Guidetti; Claudia Filippini; Chiara Benedetto
Journal:  Reprod Biol Endocrinol       Date:  2015-07-25       Impact factor: 5.211

6.  Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It?

Authors:  Nazar Mazurak; Ellen Broelz; Martin Storr; Paul Enck
Journal:  J Neurogastroenterol Motil       Date:  2015-10-01       Impact factor: 4.924

7.  Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.

Authors:  F Ziemssen; N Feltgen; F G Holz; R Guthoff; A Ringwald; T Bertelmann; A Wiedon; C Korb
Journal:  BMC Ophthalmol       Date:  2017-01-19       Impact factor: 2.209

Review 8.  The Placebo and Nocebo Responses in Clinical Trials in Inflammatory Bowel Diseases.

Authors:  Paul Enck; Sibylle Klosterhalfen
Journal:  Front Pharmacol       Date:  2021-03-31       Impact factor: 5.810

Review 9.  How Placebo Needles Differ From Placebo Pills?

Authors:  Younbyoung Chae; Ye-Seul Lee; Paul Enck
Journal:  Front Psychiatry       Date:  2018-06-05       Impact factor: 4.157

Review 10.  Placebo Responses and Placebo Effects in Functional Gastrointestinal Disorders.

Authors:  Paul Enck; Sibylle Klosterhalfen
Journal:  Front Psychiatry       Date:  2020-08-25       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.